Publications by authors named "Jeremy D Rubinstein"

Claim this Profile
O
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.
Jeremy D Rubinstein, Giang Pham, Anusha Sridharan, Ruby Khoury, YunZu M Wang

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BK polyomavirus genotype IV isolates from virus-specific T-cell therapy recipients.
Tiana A Walder, Heidi L Meeds, Michael S Grimley, Steven B Kleiboeker, Assem Ziady, Jeremy D Rubinstein

Microbiol Resour Announc· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Posttransplant EBV-Positive Smooth Muscle Tumors in Children, Adolescents, and Young Adults: A Multi-Institution Experience.
Meghan Haney, Kaitlin J Devine, Ana C Xavier, James B Ford, Anthony N Audino, Jeremy D Rubinstein

Pediatr Blood Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant.
Ruby Khoury, Michael S Grimley, Adam S Nelson, Tom Leemhuis, Jose A Cancelas, Jeremy D Rubinstein

Am J Transplant· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus-Specific T Cells for the Treatment of Systemic Infections Following Allogeneic Hematopoietic Cell and Solid Organ Transplantation.
Abby Green, Jeremy D Rubinstein, Michael Grimley, Thomas Pfeiffer

J Pediatric Infect Dis Soc· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis.
Erica F Reinig, Jeremy D Rubinstein, Apoorva T Patil, Amanda L Schussman, Vanessa L Horner

Leukemia· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Jeremy D Rubinstein, Maureen M O'Brien

Front Immunol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant lymphoproliferative disease in children, adolescents, and young adults.
Thomas G Gross, Jeremy D Rubinstein

Hematol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Thomas J Galletta, Adam Lane, Carolyn Lutzko, Thomas Leemhuis, Jose A Cancelas, Jeremy D Rubinstein

Transplant Cell Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Jeremy D Rubinstein, Erin H Breese, M Christa Krupski, Maureen M O'Brien, Christopher E Dandoy

Transplant Cell Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
Thomas J Galletta, Jeremy D Rubinstein, Christa Krupski, Adam S Nelson, Ruby Khoury

Pediatr Blood Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy.
Jonathan D Bender, Jeremy D Rubinstein, Benjamin Mizukawa, John P Perentesis, Lauren Pommert

Pediatr Blood Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Zeinab A M Afify, Mary M Taj, Manuela Orjuela-Grimm, Kavitha Srivatsa, Tamara P Miller, Jeremy D Rubinstein

Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Zeinab Afify, Manuela Orjuela-Grimm, Christine Moore Smith, Mansi Dalal, James B Ford, Jeremy D Rubinstein

Br J Haematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Valeria Ceolin, Erica Brivio, Harm van Tinteren, Susan R Rheingold, Allison Leahy, Jeremy D Rubinstein

Leukemia· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Jeremy D Rubinstein, Carolyn Lutzko, Thomas Leemhuis, Xiang Zhu, Giang Pham

Blood Adv· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia in -mutated congenital neutropenia.
Anthony Sabulski, David D Grier, Kasiani C Myers, Stella M Davies, Jeremy D Rubinstein

EJHaem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Jeremy D Rubinstein, Sonata Jodele, Daria Heyenbruch, Jamie Wilhelm, Shawn Thomas

Transplant Cell Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
Jeremy D Rubinstein, Xiang Zhu, Thomas Leemhuis, Giang Pham, Lorraine Ray

Blood Adv· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
Jeremy D Rubinstein, Rachana Shah, Erin H Breese, Karen C Burns, Jennifer L Mangino

Pediatr Blood Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis.
Myesa Emberesh, Jeremy D Rubinstein, Jennifer Young, Stefanie W Benoit, Christopher E Dandoy

Pediatr Blood Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia.
Jeremy D Rubinstein, Christa Krupski, Adam S Nelson, Maureen M O'Brien, Stella M Davies

Biol Blood Marrow Transplant· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.
Adam S Nelson, Daria Heyenbruch, Jeremy D Rubinstein, Anthony Sabulski, Sonata Jodele

Blood Adv· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy.
Jeremy D Rubinstein, Xiang Zhu, Carolyn Lutzko, Tom Leemhuis, Jose A Cancelas

Blood Adv· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities.
Jeremy D Rubinstein, Adam S Nelson, Christa Krupski, William O'Brien, J Michael Taylor

Pediatr Blood Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis